De aanbevolen abstracten staan onder elkaar in dit artikel. Als u naar ESMO 2023 gaat kunt u via de nummers van de abstracten deze vinden.
Hier een aantal aanbevolen abstracten door Rafael Fonseca MD.
Monday, October 23, 2023
16:30–18:00 CEST; Mini Oral Session
Developmental Therapeutics
660MO First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001). CA Perez
661MO Anti-tumor activity of belvarafenib in combination with cobimetinib in patients with metastatic solid tumors harboring BRAF fusions or BRAF class II/III mutation. TW Kim
Monday, October 23, 2023
16:30–18:15 CEST; Proffered Paper Session
Presidential 3
LBA13 Phase III trial of Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore). O Sartor
LBA14 Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment in Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From MARIPOSA, a Phase 3, Global, Randomized, Controlled Trial. BC Cho
LBA15 Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial. A Passaro
Sunday, October 22, 2023
10:15–11:45 CEST; Mini Oral Session
Genitourinary Tumours, Non-Prostate
1883MO MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC). MH Voss
Sunday, October 22, 2023
10:15–11:55 CEST; Mini Oral Session
Gynaecological Cancers
LBA45 Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa). JF Liu
Aanbevolen abstracten van Dr. Jeffrey Kirshner over kwaliteit van leven en overleving:
Friday, October 20, 2023
16:00–17:20 CEST; Proffered Paper Session
Supportive and Palliative Care
LBA94 Effects of short-term fasting on quality of life as an add-on option during chemotherapy. DA Koppold
2030O Remote symptom monitoring with electronic patient-reported outcomes (ePROs) during treatment for metastatic cancer: Results from the PRO-TECT trial (Alliance AFT-39). E Basch
Saturday, October 21, 2023
14:45–16:15 CEST; Mini Oral Session
Supportive and Palliative Care
LBA97 Olanzapine for the prevention of Chemotherapy Induced Nausea Vomiting in patients receiving moderately emetogenic chemotherapeutic (MEC) regimens - results of a prospective triple blinded phase 3 multicentric study (OMEC). VS Ostwal
1592MO Anticancer therapy at the end-of-life: A cluster-randomized trial. MJ Hjermstad
1593MO Combined early palliative care in patients with non small cell lung cancer: A randomised controlled trial in Chongqing, China. M Chen
1843MO The effect of chronic psychological stress on the efficacy of first-line therapy of ICIs in advanced NSCLC (STRESS-LUNG-1 trial). F Wu
Monday, October 23, 2023
16:30–18:05 CEST; Mini Oral Session
Policy and Preventive Strategies
1693MO The high burden of long-term and late health-related problems among adolescent and young adult cancer survivors: Results of the SURVAYA study. S Janssen
Aanbevolen abstracten door Dr. David Henry:
Friday, October 20, 2023
14:00–15:40 CEST; Proffered Paper Session 1
Gastrointestinal Tumours, Upper Digestive
LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): interim results of the global, Phase 3 MATTERHORN study. S-E Al-Batran
LBA74 Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The Phase 3 KEYNOTE-585 study. K Shitara
Friday, October 20, 2023
14:00–15:40 CEST; Proffered Paper Session
Breast Cancer, Early Stage
LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase 3 KEYNOTE-522 study. P Schmid
LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study. L Gianni
Friday, October 20, 2023
16:00–17:30 CEST; Proffered Paper Session
NSCLC, Metastatic
LBA63 SAPPHIRE: Phase 3 Study of Sitravatinib Plus Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC). H Borghaei
LBA64 Overall Survival from a Phase II Randomised Double-Blind Trial (PERLA) of Dostarlimab (dostar) + Chemotherapy (CT) vs Pembrolizumab (pembro) + CT in Metastatic Non-Squamous NSCLC. S Peters
Saturday, October 21, 2023
8:30–9:50 CEST; Proffered Paper Session 1
Genitourinary Tumours, Non-Prostate
LBA102 THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus Calmette-Guérin (BCG) treatment. JW Catto
Saturday, October 21, 2023
8:45–10:00 CEST; Proffered Paper Session 2
Gynecological Cancers
LBA40 Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma. N Colombo
LBA41 Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): results from the Phase III DUO-E/GOG-3041/ENGOT-EN10 trial. SN Westin
Saturday, October 21, 2023
16:30–18:15 CEST; Proffered Paper Session
Presidential 1
LBA1 CheckMate 77T: Phase 3 study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIB NSCLC. T Cascone
Gerelateerde artikelen
Plaats een reactie ...
Reageer op "ESMO 2023: aanbevolen abstracten van verschillende studies binnen personalised medicine en kwaliteit van leven door oncologen en wetenschappers"